News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ArQule, Inc. (ARQL) Plunges as Japanese Partner Temporarily Suspends Tivantinib Trial; Stock Down -1.3101 (19.55%) @ 1:19 PM EDT


8/29/2012 7:26:31 AM

ArQule, Inc. (Nasdaq: ARQL) disclosed this morning that it was informed by its Asian partner Kyowa Hakko Kirin that it has temporarily suspend patient enrollment in its ongoing Phase 3 ATTENTION trial on the recommendation of an independent Safety Review Committee in Japan after the reporting of suspected cases of interstitial lung disease in the study. From the filing: ArQule, Inc. (ArQule) has been informed by Kyowa Hakko Kirin Co., Ltd. (Kyowa), which has exclusive development rights to tivantinib in Japan and certain parts of Asia, of Kyowa’s decision to temporarily suspend patient enrollment in its ongoing Phase 3 ATTENTION (Asian Trial of Tivantinib plus Erlotinib for NSCLC without EGFR Mutation) trial.

Read at Street Insider

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES